De-risking vaccine development: lessons, challenges, and prospects
Abstract Vaccine development is long and costly. Technical, clinical, regulatory, and manufacturing risks throughout the development cycle hampered manufacturers’ efforts towards more challenging and financially less rewarding targets, with profound implications for public health. Early de-risking s...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | npj Vaccines |
| Online Access: | https://doi.org/10.1038/s41541-025-01211-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849344822541811712 |
|---|---|
| author | Vega Masignani Ricardo Palacios Marie-Thérèse Martin Fabian Tibaldi V. Kumaran Vadivelu |
| author_facet | Vega Masignani Ricardo Palacios Marie-Thérèse Martin Fabian Tibaldi V. Kumaran Vadivelu |
| author_sort | Vega Masignani |
| collection | DOAJ |
| description | Abstract Vaccine development is long and costly. Technical, clinical, regulatory, and manufacturing risks throughout the development cycle hampered manufacturers’ efforts towards more challenging and financially less rewarding targets, with profound implications for public health. Early de-risking strategies can help closing the vaccine productivity gap and support sustainable access to vaccines. Illustrated by examples of early and efficient decision-making, the herein proposed strategies can ultimately increase the success rates of vaccine programs. |
| format | Article |
| id | doaj-art-cb81f638dcbf4389a3e5d67c68f94de8 |
| institution | Kabale University |
| issn | 2059-0105 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Vaccines |
| spelling | doaj-art-cb81f638dcbf4389a3e5d67c68f94de82025-08-20T03:42:34ZengNature Portfolionpj Vaccines2059-01052025-07-011011910.1038/s41541-025-01211-zDe-risking vaccine development: lessons, challenges, and prospectsVega Masignani0Ricardo Palacios1Marie-Thérèse Martin2Fabian Tibaldi3V. Kumaran Vadivelu4GSKGSKGSKGSKGSKAbstract Vaccine development is long and costly. Technical, clinical, regulatory, and manufacturing risks throughout the development cycle hampered manufacturers’ efforts towards more challenging and financially less rewarding targets, with profound implications for public health. Early de-risking strategies can help closing the vaccine productivity gap and support sustainable access to vaccines. Illustrated by examples of early and efficient decision-making, the herein proposed strategies can ultimately increase the success rates of vaccine programs.https://doi.org/10.1038/s41541-025-01211-z |
| spellingShingle | Vega Masignani Ricardo Palacios Marie-Thérèse Martin Fabian Tibaldi V. Kumaran Vadivelu De-risking vaccine development: lessons, challenges, and prospects npj Vaccines |
| title | De-risking vaccine development: lessons, challenges, and prospects |
| title_full | De-risking vaccine development: lessons, challenges, and prospects |
| title_fullStr | De-risking vaccine development: lessons, challenges, and prospects |
| title_full_unstemmed | De-risking vaccine development: lessons, challenges, and prospects |
| title_short | De-risking vaccine development: lessons, challenges, and prospects |
| title_sort | de risking vaccine development lessons challenges and prospects |
| url | https://doi.org/10.1038/s41541-025-01211-z |
| work_keys_str_mv | AT vegamasignani deriskingvaccinedevelopmentlessonschallengesandprospects AT ricardopalacios deriskingvaccinedevelopmentlessonschallengesandprospects AT marietheresemartin deriskingvaccinedevelopmentlessonschallengesandprospects AT fabiantibaldi deriskingvaccinedevelopmentlessonschallengesandprospects AT vkumaranvadivelu deriskingvaccinedevelopmentlessonschallengesandprospects |